Safety and efficacy of surgical implantation of intrathecal drug delivery pumps in patients with cancer with refractory pain Journal Article
| Authors: | Winston, G. M.; Zimering, J. H.; Newman, C. W.; Reiner, A. S.; Manalil, N.; Kharas, N.; Gulati, A.; Rakesh, N.; Laufer, I.; Bilsky, M. H.; Barzilai, O. |
| Article Title: | Safety and efficacy of surgical implantation of intrathecal drug delivery pumps in patients with cancer with refractory pain |
| Abstract: | BACKGROUND AND OBJECTIVES: Pain management in patients with cancer is a critical issue in oncology palliative care as clinicians aim to enhance quality of life and mitigate suffering. Most patients with cancer experience cancer-related pain, and 30%-40% of patients experience intractable pain despite maximal medical therapy. Intrathecal pain pumps (ITPs) have emerged as an option for achieving pain control in patients with cancer. Owing to the potential benefits of ITPs, we sought to study the long-term outcomes of this form of pain management at a cancer center. METHODS: We retrospectively reviewed medical records of all adult patients with cancer who underwent ITP placement at a tertiary comprehensive cancer center between 2013 and 2021. Baseline characteristics, preoperative and postoperative pain control, and postoperative complication rate data were collected. RESULTS: A total of 193 patients were included. We found that the average Numerical Rating Scale (NRS) score decreased significantly by 4.08 points (SD = 2.13, P <.01), from an average NRS of 7.38 (SD = 1.64) to an average NRS of 3.27 (SD = 1.66). Of 185 patients with preoperative and follow-up NRS pain scores, all but 9 experienced a decrease in NRS (95.1%). The median overall survival from time of pump placement was 3.62 months (95% CI: 2.73-4.54). A total of 42 adverse events in 33 patients were reported during the study period. The 1-year cumulative incidence of any complication was 15.6% (95% CI: 10.9%-21.1%) and for severe complication was 5.7% (95% CI: 3.0%-9.7%). Eleven patients required reoperation during the study period, with a 1-year cumulative incidence of 4.2% (95% CI: 2.0%-7.7%). CONCLUSION: Our study demonstrates that ITP implantation for the treatment of cancer-related pain is a safe and effective method of pain palliation with a low complication rate. Future prospective studies are required to determine the optimal timing of ITP implantation. © 2024 Congress of Neurological Surgeons. All rights reserved. |
| Keywords: | palliative care; cancer pain; intrathecal pump; oncology pain |
| Journal Title: | Neurosurgery |
| Volume: | 95 |
| Issue: | 5 |
| ISSN: | 0148-396X |
| Publisher: | Wolters Kluwer |
| Date Published: | 2024-11-01 |
| Start Page: | 1072 |
| End Page: | 1081 |
| Language: | English |
| DOI: | 10.1227/neu.0000000000002978 |
| PUBMED: | 38700319 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledge in the PDF -- Corresponding authors is MSK author: Ori Barzilai -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work